#ASC37
Ascletis Pharma Unveils Groundbreaking Obesity Treatments at ObesityWeek® 2026#USA#Washington,_DC#Ascletis_Pharma#ASC37#ASC48
Ascletis Pharma Unveils Groundbreaking Obesity Treatments at ObesityWeek® 2026
Ascletis Pharma is set to showcase two innovative obesity treatments at ObesityWeek® 2026, highlighting their latest preclinical research.
third-news.com
November 2, 2026 at 8:59 AM
Ascletis Unveils ASC37: A Game-Changer in Weight Loss Treatments with Monthly Dosing#None#weight_loss#Ascletis#ASC37
Ascletis Unveils ASC37: A Game-Changer in Weight Loss Treatments with Monthly Dosing
Ascletis Pharma has introduced ASC37, an innovative weight loss treatment with monthly administration, showing remarkable results in obese mice.
third-news.com
July 27, 2026 at 10:20 AM
Ascletis Advances ASC37: A Promising Once-Monthly Treatment for Obesity#China#Hong_Kong#Ascletis#Obesity_Treatment#ASC37
Ascletis Advances ASC37: A Promising Once-Monthly Treatment for Obesity
Ascletis Pharma has developed ASC37, a new triple peptide agonist for obesity treatment, showcasing a significantly longer half-life and compelling effectiveness.
third-news.com
January 20, 2026 at 9:04 AM
Ascletis Moves Forward with ASC37: A Promising Triple Peptide Agonist for Obesity Treatment#China#Hong_Kong#Ascletis#ASC37#Peptide_Agonist
Ascletis Moves Forward with ASC37: A Promising Triple Peptide Agonist for Obesity Treatment
Ascletis announces its first oral GLP-1R/GIPR/GCGR triple peptide agonist, ASC37, aimed at obesity treatment, leveraging its proprietary technology.
third-news.com
November 30, 2025 at 10:27 AM
LucidQuest YouTube > Trending in Obesity: CT-388 hits 22.5%, AZ–CSPC deal and more: Roche’s CT-388 shows up to 22.5 percent placebo-adjusted weight loss at 48 weeks, with Phase 3 this quarter. Chugai and Roche advance muscle-sparing adjunct GYM329 to curb… Subscribe for more! #LucidQuest #PharmaCI
Trending in Obesity: CT-388 hits 22.5%, AZ–CSPC deal and more
Roche’s CT-388 shows up to 22.5 percent placebo-adjusted weight loss at 48 weeks, with Phase 3 this quarter. Chugai and Roche advance muscle-sparing adjunct GYM329 to curb rebound after GLP-1s. Regeneron positions olatorepatide for weight loss plus 50–60 percent LDL-C reduction. AstraZeneca licenses eight monthly programs from CSPC for 1.2 billion dollars upfront. Ascletis picks once-monthly triple agonist ASC37. Hanmi files efpeglenatide in Korea. Corxel raises 287 million dollars for oral GLP-1 CX11; MASH efinopegdutide topline H1.
www.youtube.com
February 3, 2026 at 12:02 PM